Dai Cheng

USPTO Granted Patents = 10 (Patent Applications = 5)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 52(Granted Patents)

Company Filing History:

Irm Llc, a Delware Limited Corporation

patent

Years Active: 2011-2019

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10251893 - N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators (2019-04-09),

2. 9238646 - N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators (2016-01-19),

3. 9216964 - Hedgehog pathway modulators (2015-12-22),

4. 9181235 - Substituted pyridines for modulating the WNT signaling pathway (2015-11-10),

5. 8546396 - N-(hetero)aryl, 2-(hetero)aryl—substituted acetamides for use as Wnt signaling modulators (2013-10-01),

6. 8507491 - Compounds and compositions as hedgehog pathway inhibitors (2013-08-13),

7. 8178563 - Compounds and compositions as hedgehog pathway modulators (2012-05-15),

8. 8178526 - Compounds and compositions as ITPKb inhibitors (2012-05-15),

9. 8101608 - Compounds and compositions as protein kinase inhibitors (2012-01-24),

10. 7928133 - Compounds and compositions as hedgehog signaling pathway modulators (2011-04-19),

Title: Innovator Spotlight on Dai Cheng - A Pioneer in Wnt Signaling Research

Introduction

Dai Cheng is a notable inventor based in San Diego, California, renowned for his contributions to the field of biochemistry and molecular biology. With a remarkable record of ten patents, he has become a significant figure in advancing the understanding and manipulation of the Wnt signaling pathway, a crucial regulator of various biological processes.

Latest Patents

Cheng's latest innovations include two pivotal patents that explore the use of N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides as Wnt signaling modulators. The patents outline methods and compositions focused on modulating the Wnt signaling pathway using compounds of Formula (1). These innovations are expected to play an essential role in therapeutic applications aimed at addressing diseases linked to Wnt signaling disruptions.

Career Highlights

Throughout his career, Dai Cheng has had the opportunity to work with eminent companies such as Irm LLC and Novartis AG. His tenure at these organizations has enabled him to collaborate on groundbreaking research projects and further his expertise in biotechnology and pharmaceuticals.

Collaborations

Cheng has worked alongside distinguished colleagues, including Shifeng Pan and Dong Han. Their collaborative efforts have contributed to the successful development of innovative strategies and solutions in their field, reinforcing the importance of teamwork in scientific advancement.

Conclusion

Dai Cheng's innovative venture into Wnt signaling modulation showcases his dedication to advancing scientific knowledge and developing novel therapeutic methodologies. With a solid patent portfolio and collaborations with industry leaders, he continues to be a driving force in biochemistry innovation, poised to make a lasting impact on healthcare and molecular biology.

This text is generated by artificial intelligence and may not be accurate.